UB Paderborn / Katalog / Suche / in CDI

ERROR: Record not found

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

Blood, 2016-01, Vol.127 (1), p.29-41

2016

Volltextzugriff (PDF)

A systematic review of the evidence for Canada's Physical Activity Guidelines for Adults

The international journal of behavioral nutrition and physical activity, 2010-05, Vol.7 (1), p.39-39

2010

Volltextzugriff (PDF)

Assessment of Minimal Residual Disease in Standard-Risk AML

The New England journal of medicine, 2016-02, Vol.374 (5), p.422-433

2016

Volltextzugriff (PDF)

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood, 2022-12, Vol.140 (22), p.2407-2411

2022

Volltextzugriff (PDF)

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

The Journal of experimental medicine, 2016-07, Vol.213 (8), p.1513-1535

2016

Volltextzugriff (PDF)

Exercise volume and intensity: a dose–response relationship with health benefits

European journal of applied physiology, 2014-08, Vol.114 (8), p.1563-1571

2014

Volltextzugriff (PDF)

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Blood advances, 2021-12, Vol.5 (23), p.5107-5111

2021

Volltextzugriff (PDF)

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES

HemaSphere, 2023-08, Vol.7 (S3), p.e345570d-n/a

2023

Volltextzugriff (PDF)

Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot–Leyden crystals

International journal of hematology, 2013-09, Vol.98 (3), p.267-268

2013

Volltextzugriff (PDF)

Long-term ultra-marathon running and arterial compliance

Journal of science and medicine in sport, 2014-05, Vol.17 (3), p.322-325

2014

Volltextzugriff (PDF)

Physiological demands of downhill mountain biking

Journal of sports sciences, 2012-12, Vol.30 (16), p.1777-1785

2012

Volltextzugriff (PDF)

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Journal of clinical oncology, 2020-10, Vol.38 (30), p.3506-3517

2020

Volltextzugriff (PDF)

Characterisation of baroreflex sensitivity of recreational ultra-endurance athletes

European journal of sport science, 2014-01, Vol.14 (7), p.686-694

2014

Volltextzugriff (PDF)

Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes

Blood, 2022-11, Vol.140 (Supplement 1), p.6258-6259

2022

Volltextzugriff (PDF)

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

British journal of haematology, 2021-03, Vol.192 (6), p.1026-1030

2021

Volltextzugriff (PDF)

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.1453-1455

2022

Volltextzugriff (PDF)

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Blood, 2023-11, Vol.142 (Supplement 1), p.1577-1577

2023

Volltextzugriff (PDF)

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Blood, 2023-11, Vol.142 (Supplement 1), p.425-425

2023

Volltextzugriff (PDF)

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood, 2024-05, Vol.143 (19), p.1931-1936

2024

Volltextzugriff (PDF)

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

Journal of clinical oncology, 2024-06, Vol.42 (18), p.2161

2024

Volltextzugriff (PDF)

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.1261-1261

2021

Volltextzugriff (PDF)

Cellular distribution of IDH mutations in AML during morphologic remission

Leukemia research, 2023-01, Vol.124, p.106993-106993, Article 106993

2023

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(101)

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(47)
Humans
(35)
Male
(20)
Female
(18)
Middle Aged
(16)
Hematology
(14)
Adult
(13)
Leukemia, Myeloid, Acute - Genetics
(13)
Aged
(12)
Mutation
(9)
Nuclear Proteins - Genetics
(9)
Leukemia, Myeloid, Acute - Drug Therapy
(8)
Nucleophosmin
(8)
Sport Sciences
(8)
Leukemia, Myeloid, Acute - Pathology
(7)
Prognosis
(7)
Oncology
(6)
Physiology
(6)
Animals
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

A systematic review of the evidence for Canada's Physical Activity Guidelines for Adults

Assessment of Minimal Residual Disease in Standard-Risk AML

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

Exercise volume and intensity: a dose–response relationship with health benefits

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES

Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot–Leyden crystals

Long-term ultra-marathon running and arterial compliance

Physiological demands of downhill mountain biking

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Characterisation of baroreflex sensitivity of recreational ultra-endurance athletes

Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

Cellular distribution of IDH mutations in AML during morphologic remission

Suchergebnisse filtern